Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease

详细信息    查看全文

• 作者：Lorenzo Leggio ; MD ; PhD ; MSc^a ; ^b ; ^{lorenzo.leggio@nih.gov} ; Mary R. Lee ; MD^a ; ^{leemary@mail.nih.gov}
• 关键词：Alcohol use disorder ; Alcoholic liver disease ; Liver disease ; Treatment
• 刊名：The American Journal of Medicine
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：130
• 期：2
• 页码：124-134
• 全文大小：1093 K
• 卷排序：130

文摘

Alcohol is a leading cause of liver disease worldwide. Although alcohol abstinence is the crucial therapeutic goal for patients with alcoholic liver disease, these patients have less access to psychosocial, behavioral, and/or pharmacologic treatments for alcohol use disorder. Psychosocial and behavioral therapies include 12-step facilitation, brief interventions, cognitive behavioral therapy, and motivational enhancement therapy. In addition to medications approved by the US Food and Drug Administration for alcohol use disorder (disulfiram, naltrexone, and acamprosate), recent efforts to identify potential new treatments have yielded promising candidate pharmacotherapies. Finally, more efforts are needed to integrate treatments across disciplines toward patient-centered approaches in the management of patients with alcohol use disorder and alcoholic liver disease.